ES2089011T3 - Excipiente lipidico de administracion nasal y aplicacion topica. - Google Patents

Excipiente lipidico de administracion nasal y aplicacion topica.

Info

Publication number
ES2089011T3
ES2089011T3 ES90904004T ES90904004T ES2089011T3 ES 2089011 T3 ES2089011 T3 ES 2089011T3 ES 90904004 T ES90904004 T ES 90904004T ES 90904004 T ES90904004 T ES 90904004T ES 2089011 T3 ES2089011 T3 ES 2089011T3
Authority
ES
Spain
Prior art keywords
lipid
excipient
topical application
relatively low
nasal administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904004T
Other languages
English (en)
Inventor
Alan L Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Application granted granted Critical
Publication of ES2089011T3 publication Critical patent/ES2089011T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Abstract

SE DESCRIBEN METODOS Y COMPUESTOS EN FORMA LIQUIDA O EN GEL, DE UN EXCIPIENTE LIPIDO PARA USO EN PREPARACIONES FARMACEUTICAS O EN COSMETICA. EL EXCIPIENTE LIPIDO COMPRENDE UN FOSFOLIPIDO TAL COMO UN LYSOFOSFOLIPIDO POR EJEMPLO: MONO-OLEOYL-PHOSPHATIDYLLETHANO LAMINE ("MOPE"). UNA RELATIVAMENTE BAJA CONCENTRACION DE LIPIDO SE PUEDE UTILIZAR PARA COMPONER EL GEL APROX: 1-2%. LA INVENCION DESCUBRE EL USO DE UN SISTEMA DE SUMINISTRO A UNA RELATIVAMENTE BAJA CONCENTRACION COMO PORTADOR NO TOXICO, NO IRRITANTE, O COMO EXCIPIENTE, O EN COMBINACION CON OTRAS SUBSTANCIAS TANTO PARA MEDICAMENTOS, COMO PARA COSMETICA. POR EJEMPLO: EL EXCIPIENTE LIPIDO TANTO EN PULVERIZADO COMO EN GOTAS CONLLEVA UNA EXCEPCIONAL UTILIDAD EN EL SUMINITRO DE PEPTIDOS NO IRRITANTES EJ: (CALCITONINA E INSULINA) EN LA MUCOSA NASAL DEBIDO A LA ABILIDAD DEL EXCIPIENTE EN MEJORAR EL VALOR DE ABSORCION A TRAVES DE LAS MEMBRANAS NASALES. COMO COSMETICO, PUEDE SER UTILIZADO SOLO O EN UN COMPUESTO CON AGENTES BIOLOGICAMENTE ACTIVOS.
ES90904004T 1989-02-17 1990-02-14 Excipiente lipidico de administracion nasal y aplicacion topica. Expired - Lifetime ES2089011T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31251289A 1989-02-17 1989-02-17

Publications (1)

Publication Number Publication Date
ES2089011T3 true ES2089011T3 (es) 1996-10-01

Family

ID=23211791

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90904004T Expired - Lifetime ES2089011T3 (es) 1989-02-17 1990-02-14 Excipiente lipidico de administracion nasal y aplicacion topica.

Country Status (11)

Country Link
US (1) US5200393A (es)
EP (1) EP0458894B1 (es)
JP (1) JPH05500203A (es)
KR (1) KR0157428B1 (es)
AT (1) ATE138071T1 (es)
AU (1) AU639228B2 (es)
CA (1) CA2045469A1 (es)
DE (1) DE69027022T2 (es)
DK (1) DK0458894T3 (es)
ES (1) ES2089011T3 (es)
WO (1) WO1990009385A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891466A (en) * 1990-08-13 1999-04-06 Yesair; David W. Mixed Liped-Bicarbonate colloidal particles for delivering drugs or calories
US6419850B1 (en) * 1991-06-03 2002-07-16 Airel-West System and composition for decontaminating fluids
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
EP0806945B1 (en) * 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US20030059440A1 (en) * 1998-09-01 2003-03-27 Tim Clarot Composition and method for moisturizing nasal tissue
DK1031347T3 (da) * 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
JP4932086B2 (ja) * 1999-04-08 2012-05-16 インターセル ユーエスエイ、インコーポレイテッド 経皮的免疫のための乾燥製剤
JP2003501404A (ja) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法
US6489312B1 (en) * 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6432383B1 (en) 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
WO2002064162A2 (en) * 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
KR20030065965A (ko) * 2002-02-02 2003-08-09 주식회사 두산 리소포스파티딜에탄올아민을 유효성분으로 함유하는 피부미백용 조성물
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
CN100355455C (zh) * 2002-07-15 2007-12-19 爱尔康公司 用于眼内使用的非聚合亲脂性药物植入组合物
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP2316418A3 (en) * 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
BRPI0613540A2 (pt) * 2005-06-03 2011-01-18 Elan Pharma Int Ltd formulações de imatinib mesilato nanoparticuladas
AU2008279584A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
JP5341532B2 (ja) * 2009-01-19 2013-11-13 第一電子工業株式会社 １対の誤嵌合防止キー及び該キーを用いた電気コネクタ
DE102009008094A1 (de) 2009-02-09 2010-08-19 Barnikol-Keuten, Doris, Dr. In situ Haft-Gelbildende Zubereitungen, insbesondere zur topischen Anwendung auf befeuchtete Haut/Schleimhaut
CZ308596B6 (cs) * 2017-04-03 2020-12-23 Ústav molekulární genetiky AV ČR, v. v. i. Deriváty fosfolipidů a jejich použití jako léčiva

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159988A (en) * 1974-08-06 1979-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic phospholipids, a process for their manufacture and their use
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
US4619795A (en) * 1984-12-24 1986-10-28 Technicon Instruments Corp. Method for preparing lipid vesicles
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Also Published As

Publication number Publication date
DK0458894T3 (da) 1996-10-07
CA2045469A1 (en) 1990-08-18
AU5173690A (en) 1990-09-05
US5200393A (en) 1993-04-06
AU639228B2 (en) 1993-07-22
WO1990009385A1 (en) 1990-08-23
EP0458894A1 (en) 1991-12-04
DE69027022T2 (de) 1996-11-28
KR920700679A (ko) 1992-08-10
DE69027022D1 (de) 1996-06-20
EP0458894A4 (en) 1991-10-01
KR0157428B1 (ko) 1998-11-16
JPH05500203A (ja) 1993-01-21
ATE138071T1 (de) 1996-06-15
EP0458894B1 (en) 1996-05-15

Similar Documents

Publication Publication Date Title
ES2089011T3 (es) Excipiente lipidico de administracion nasal y aplicacion topica.
ES2526707T3 (es) Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
DE69428040D1 (de) Orale darreichungsform
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
ATE225647T1 (de) Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
RU95112536A (ru) Способы пульсирующего системного введения активного фрагмента паратиреоидного гормона (ртн) и фармацевтические композиции, содержащие биологически активный n-концевой фрагмент паратиреоидного гормона (ртн)
BR9906920A (pt) "tts contendo um antioxidante"
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
DE69114508T2 (de) Amphiphile fluorderivate mit telomerer struktur und biomedizinische anwendungen.
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
ATE353009T1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
ATE364391T1 (de) Arzneiformulierung enthaltend ciclosporin und deren verwendung
KR960702847A (ko) 생물학적 활성의 바소프레신 유사체
EP1684681B1 (en) A mixture for transdermal delivery of low and high molecular weight compounds
AU625402B2 (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
KR0137206B1 (ko) 분무용 겔 기제와 이것을 사용한 분무용 겔제
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
JP2001505222A (ja) 生物体にペプチド系医薬を導入するための局所用製剤
RU94010496A (ru) Ноотропное средство и лекарственный состав ноотропного средства
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
GB763168A (en) Inhalant preparation
IT9020946A0 (it) Composizione farmaceutica liquida per la somministrazione nasale contenente un polipeptide come sostanza attiva

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 458894

Country of ref document: ES

FG2A Definitive protection

Ref document number: 458894

Country of ref document: ES